Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported R&D Expense of $2.11 million for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.11M | -57.8% |
| 2024 | $4.99M | +620.8% |
| 2023 | $691.8K | +31.6% |
| 2022 | $525.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $809.8K | -13.9% | +224.1% |
| June 30, 2025 | $249.9K | -91.9% | -38.7% |
| March 31, 2025 | $407.6K | +20.9% | -56.6% |
| September 30, 2024 | $940.1K | +256.5% | -69.6% |
| June 30, 2024 | $3.10M | +1418.3% | +818.0% |
| March 31, 2024 | $337.2K | +171.9% | +27.9% |
| September 30, 2023 | $263.7K | +853.5% | +29.3% |
| June 30, 2023 | $203.9K | -11.9% | +64.4% |
- 60 DEGREES PHARMACEUTICALS, INC. showed a decrease of -57.8% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, 60 DEGREES PHARMACEUTICALS, INC.’s r&d expense has grown by 300.7% (from $525.6 thousand to $2.11 million).
- The most recent figure is from 60 DEGREES PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: